FDA Exacts Tougher Labels For Anti-Psychotic Drugs
The U.S. Food and Drug Administration has opted for a stiffer warning for an older class of anti-psychotic drugs that includes Johnson & Johnson's Risperdal, concerned that even this "conventional" line...To view the full article, register now.
Already a subscriber? Click here to view full article